Chemical structures of ABT-737 (left) and ABT-263 (right ). | Download Scientific Diagram
Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells
ABT-737 - Wikipedia
Schematic summary of the effects of ABT-737 on human oral cancer cells.... | Download Scientific Diagram
PDF] Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. | Semantic Scholar
Cancers | Free Full-Text | The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B | Cell Death & Disease
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized - ScienceDirect
Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-Based Respirometry | PLOS ONE
ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin–DNA adducts - ScienceDirect
Frontiers | BH3 Mimetics for the Treatment of Prostate Cancer
Ionizing Radiation Sensitizes Breast Cancer Cells to Bcl-2 Inhibitor, ABT- 737, through Regulating Mcl-1
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells | Leukemia
ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells [PeerJ]
Mechanisms of potentiation of ABT-737 lethality by strategies targeting... | Download Scientific Diagram
ABT-737 is a Selective and BH3 Mimetic Bcl-2, Bcl-xL and Bcl-w Inhibitor - Network of Cancer Research
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B | Cell Death & Disease
ABT-737 | ≥99%(HPLC) | Selleck | Bcl-2 阻害剤
ABT-737 and Roscovitine induces apoptosis in a synergistic fashion in mast cells carrying the D816V KIT mutation
Frontiers | Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors